The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody

Journal of the American Academy of Dermatology
K PappM R Garovoy

Abstract

Anti-CD11a (hu1124) is a humanized monoclonal antibody directed against the CD11a subunit of LFA-1. This study investigated whether treatment with anti-CD11a antibody provides clinical benefit to patients with moderate to severe plaque psoriasis. This was a double-blind, placebo-controlled, phase II, multicenter study. In total, 145 patients with minimum Psoriasis Area and Severity Index scores of 12 and affected body surface area of 10% or more were sequentially enrolled into low-dose (0.1 mg/kg, n = 22) or high-dose (0.3 mg/kg, n = 75) groups. Within groups, patients were randomized to treatment or placebo (n = 48) in a 2:1 ratio. Drug was administered intravenously at weekly intervals for 8 weeks. The percentage of subjects achieving more than 50% improvement in physician's global assessment at day 56 (1 week after final dose) was 15% and 48% for placebo and 0.3 mg/kg of drug, respectively (P =.002). A physician's global assessment of excellent (>75% improvement) was greater in the 0.3 mg/kg group versus placebo (25% vs 2%, P =.0003). Average Psoriasis Area and Severity Index scores at day 56 were 13.9 +/- 7.5 (placebo) and 10.9 +/- 8.4 (0.3 mg/kg) (P <.0001). Epidermal thickness was reduced in the 0.3 mg/kg group compared w...Continue Reading

Citations

May 15, 2007·Archives of Dermatological Research·A NastB Rzany
Jul 28, 2004·The American Journal of Pathology·Christopher G KevilDaniel C Bullard
Nov 4, 2009·Molecular Pharmaceutics·Chuda ChittasuphoCory Berkland
Feb 3, 2005·Nature Reviews. Drug Discovery·Alice B Gottlieb
Apr 23, 2002·The British Journal of Dermatology·B Kirby, C E M Griffiths
Dec 21, 2002·International Journal of Dermatology·Don MehrabiCalvin O McCall
Nov 25, 2003·The New England Journal of Medicine·Mark LebwohlUNKNOWN Efalizumab Study Group
Jan 15, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·V SchleyerR-M Szeimies
Mar 24, 2005·Dermatology : International Journal for Clinical and Investigative Dermatology·Jochen Schmitt, Gottfried Wozel
Jun 26, 2007·Skin Pharmacology and Physiology·B BonnekohH Gollnick
Dec 29, 2005·Proceedings of the National Academy of Sciences of the United States of America·Michelle A LowesJames G Krueger
Apr 10, 2002·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·T Jung
Jul 2, 2005·Expert Opinion on Emerging Drugs·Robert Gniadecki, Martin J Calverley
Jul 2, 2003·Expert Opinion on Investigational Drugs·Jean KanitakisAlain Claudy
Jan 11, 2011·Expert Opinion on Drug Safety·Marina TalamontiSergio Chimenti
Jul 25, 2006·Expert Opinion on Investigational Drugs·Daniel BockGerhard Wolff
Jun 4, 2004·Expert Opinion on Biological Therapy·Jane Barry, Brian Kirby
Apr 30, 2003·Expert Opinion on Biological Therapy·Russell L DedrickMarvin R Garovoy
May 25, 2004·Expert Opinion on Investigational Drugs·Sheila A Doggrell
Jul 20, 2006·Journal of Pharmaceutical Sciences·Alison L DunehooTeruna J Siahaan
Feb 12, 2004·The Journal of Investigative Dermatology. Symposium Proceedings·Alice B Gottlieb
Oct 30, 2003·The Journal of Investigative Dermatology. Symposium Proceedings·Vera H Price
Jan 8, 2004·The Journal of Investigative Dermatology·Michael P SchönW Henning Boehncke
Nov 14, 2007·Regulatory Toxicology and Pharmacology : RTP·Janet ClarkeJoy Cavagnaro
Aug 26, 2004·The British Journal of Dermatology·C C Jacobson, A B Kimball
Jul 24, 2004·The British Journal of Dermatology·T KormeiliP S Yamauchi
Oct 21, 2005·Immunology·Roberto González-AmaroFrancisco Sánchez-Madrid
Aug 29, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·D PathiranaB Rzany
Jun 20, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Jeffrey B MatthewsJeffrey A Bluestone
Apr 19, 2003·Journal of the European Academy of Dermatology and Venereology : JEADV·J C Prinz
Aug 23, 2006·Chemical Biology & Drug Design·Meagan E AndersonTeruna J Siahaan
Dec 26, 2006·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Alexander NastUNKNOWN Germany Society for Dermatology
Jul 11, 2007·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Alexander NastUNKNOWN Berufsverband Deutscher Dermatologen (BVDD)
May 17, 2006·International Journal of Dermatology·Kim A PappUNKNOWN Efalizumab Study Group
Oct 13, 2006·The Australasian Journal of Dermatology·Michael R Lee, Alan J Cooper
Nov 18, 2004·Regulatory Toxicology and Pharmacology : RTP·Janet ClarkeJoseph Beyer
Feb 21, 2006·Journal of the American Academy of Dermatology·Wayne CareyDarryl Toth

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.